Study wrapper · #987
2025 FDA TIDES (Peptides and Oligonucleotides) Harvest.
AlShaer D, Al Musaimi O, Albericio F, et al. Pharmaceuticals (Basel, Switzerland). 2026.
DOI: 10.3390/ph19020244PubMed: 41754785
Editor's note
A review of 2025 FDA peptide and oligonucleotide approvals that documents elamipretide's approval for Barth syndrome, a specific inherited condition. A notable regulatory milestone for the peptide, though the approval is narrow and disease-specific. Useful context for SS-31 coverage.
Plain-language abstract
This review of 2025 FDA-approved peptide and oligonucleotide drugs notes that elamipretide became the first approved therapy for Barth syndrome.
Related coverage
Weak / none
Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.
Tissue & celln=——2026
Weak / none
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.
Journal of radiation researchn=——2026
Supported
Elamipretide: a mitochondria-targeting drug for Barth syndrome.
Trends in pharmacological sciencesn=——2026